Skip to content
Back to ATRA

Atara Biotherapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
15
Purchases
2
Sales
13
Purchase value
$5.74M
Sale value
$3.79M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Brian N CherryDirector
4
Filed Sep 4, 2026Period of report Sep 4, 20260000905148-26-004085
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseSep 4, 2026
Common StockF1104,166$9.60$999.99K166,486Direct
Filing footnotes · 1
  1. F1Represents shares purchased by the Reporting Person from the Issuer, through its sales agent, pursuant to that certain Sales Agreement, dated November 1, 2023, by and between the Issuer and TD Securities (USA) LLC.
Open on SEC EDGAR
AnhCo NguyenDirector · President and CEO
4
Filed Aug 26, 2026Period of report Aug 17, 20260000905148-26-003960
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 17, 2026
Common StockF1F25,062$8.0764$40.88K132,775Direct
Filing footnotes · 2
  1. F1Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  2. F2The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open on SEC EDGAR
AnhCo NguyenDirector · President and CEO
4
Filed May 20, 2026Period of report May 18, 20260000905148-26-002571
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 18, 2026
Common StockF1F25,241$9.1289$47.84K137,837Direct
Filing footnotes · 2
  1. F1Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  2. F2Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open on SEC EDGAR
Yanina Grant-HuertaChief Accounting Officer
4
Filed May 20, 2026Period of report May 18, 20260000905148-26-002570
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 18, 2026
Common StockF1F22,414$9.1286$22.04K49,636Direct
Filing footnotes · 2
  1. F1Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  2. F2Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open on SEC EDGAR
James HuangDirector · 10% owner
Panacea Innovation Ltd10% owner
4
Filed May 11, 2026Period of report May 7, 20260001193125-26-217380
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 7, 2026
Common StockF1F2F3313,446$10.0975$3.17M1,011,000IndirectSee Footnote
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.50, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  2. F2Represents securities held by Panacea Venture Healthcare Fund II, L.P.
  3. F3James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. ("Fund II GP") and Panacea Opportunity Fund I GP Company, Ltd. ("Opportunity Fund GP"), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
  4. F4Represents securities held by Panacea Opportunity Fund I, L.P.
Open on SEC EDGAR
EcoR1 Capital, LLC10% owner
4
Filed May 11, 2026Period of report May 7, 20260000935836-26-000239
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 7, 2026
Common StockF2F3F4F1507,407$9.35$4.74M1,552,000IndirectSee Note
Filing footnotes · 4
  1. F1The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
  2. F2Qualified Fund purchased 474,780 of the shares puchased in this transaction.
  3. F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. F4After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock.
Open on SEC EDGAR
Yanina Grant-HuertaChief Accounting Officer
4
Filed Mar 4, 2026Period of report Mar 2, 20260000905148-26-001144
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF1F2F324$5.077$121.8533,830Direct
SaleMar 2, 2026
Common StockF1F21,603$5.081$8.14K32,227Direct
SaleMar 2, 2026
Common StockF1F2377$5.082$1.92K31,850Direct
SaleMar 2, 2026
Common StockF1F2100$5.083$508.3031,750Direct
Filing footnotes · 3
  1. F1Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  2. F2The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
  3. F3This amount includes 400 shares purchased under the Issuer's Employee Stock Purchase Plan on November 28, 2025.
Open on SEC EDGAR
AnhCo NguyenDirector · President and CEO
4
Filed Mar 4, 2026Period of report Mar 2, 20260000905148-26-001143
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF1F2198$5.079$1.01K64,776Direct
SaleMar 2, 2026
Common StockF1F258$5.08$294.6464,718Direct
SaleMar 2, 2026
Common StockF1F21,298$5.086$6.60K63,420Direct
SaleMar 2, 2026
Common StockF1F21,442$5.087$7.34K61,978Direct
Filing footnotes · 2
  1. F1Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
  2. F2The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Open on SEC EDGAR
James HuangDirector · 10% owner
Panacea Innovation Ltd10% owner
4
Filed Jan 14, 2026Period of report Jan 12, 20260001193125-26-013358
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 12, 2026
Common StockF3F1F280,554$6.0707$489.02K1,324,446IndirectSee Footnotes
Filing footnotes · 4
  1. F1Represents securities held by Panacea Venture Healthcare Fund II, L.P.
  2. F2James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. ("Fund II GP") and Panacea Opportunity Fund I GP Company, Ltd. ("Opportunity Fund GP"), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.9888 to $6.2838, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. F4Represents securities held by Panacea Opportunity Fund I, L.P.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.